Online Investor Kit

Online Investor Kit

Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

Date Documents

Recent SEC Filings

Filing date Form Description Filing Group Downloads
8-K

Report of unscheduled material events or corporate event

Current Reports
SC 13G/A

An amendment to the SC 13G filing

3,4,5
SC 13G/A

An amendment to the SC 13G filing

3,4,5
SC 13G/A

An amendment to the SC 13G filing

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5

Fact Sheets

There are currently no items available.

Recent Press Releases

Date Title and Summary
Toggle Summary Pacira Reports Record Fourth Quarter and Full-Year Revenues
— Full-year 2019 revenue increases 25 percent to $421 million versus 2018 — — Total 2020 revenue guidance of between $485 million and $500 million — — Anesthesia-driven regional approaches are expanding and driving strong EXPAREL growth — — Conference call today at 8:30 a.m. ET — PARSIPPANY, N.J.
Toggle Summary Pacira to Report 2019 Financial Results on Thursday February 20, 2020
PARSIPPANY, N.J. , Feb. 13, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2019 financial results before the open of the U.S. markets on Thursday, February 20, 2020 .
Toggle Summary Pacira BioSciences Launches National Regional Anesthesia Training Initiative with Envision Physician Services
The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain PARSIPPANY, N.J. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a
Toggle Summary Pacira BioSciences Reports Full-Year 2019 Preliminary Revenue of $421.0 Million
Fourth quarter preliminary revenue of $122.4 million increased 29% compared with 2018 PARSIPPANY, N.J. , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net revenue
Toggle Summary Pacira BioSciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J. , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 38 th Annual J.P. Morgan Healthcare Conference at 9:30 AM PT ( 12:30 PM ET ) on Wednesday, January 15, 2020 . Live audio of the event can be accessed by visiting
Toggle Summary EXPAREL Achieves Primary and Key Secondary Endpoints in Phase 4 CHOICE Study in Cesarean Section Patients
EXPAREL TAP block superior to morphine spinal–based standard of care PARSIPPANY, N.J. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that its Phase 4 study of EXPAREL ® (bupivacaine liposome injectable suspension) in patients undergoing Cesarean section
Toggle Summary Pacira BioSciences Announces Positive Results from Phase 3 PLAY Study of EXPAREL® in Pediatric Patients
-- New data expected to support expansion of EXPAREL label to include children aged six and over -- PARSIPPANY, N.J. , Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc . (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced positive results
Toggle Summary Pacira BioSciences to Present at the 31st Annual Piper Jaffray Healthcare Conference
PARSIPPANY, N.J. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 31 st Annual Piper Jaffray Healthcare Conference at 9:30 AM on Tuesday, December 3, 2019 . Live audio of the event can be accessed by visiting the “Events” page of
Toggle Summary Pacira BioSciences to Present at the Jefferies 2019 London Healthcare Conference
PARSIPPANY, N.J. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the Jefferies 2019 London Healthcare Conference at 2:40 PM GMT ( 9:40AM ET ) on Wednesday, November 20, 2019 . Live audio of the event can be accessed by visiting the
Toggle Summary Pacira BioSciences Reports Third Quarter 2019 Financial Results and Business Update
-- Total revenues increased 25 percent over prior year to $104.7 million in third quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options,